JEFFREY JOHANNES: Open Payments
NPI 1346203049 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,315 in 75 payments from 21 companies in 2025. Trend: 2023 $883 · 2024 $1,219 · 2025 $1,315
Food & beverage: $1,315
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $351 |
| Novo Nordisk Inc | 9 | $145 |
| Lilly USA, LLC | 8 | $129 |
| AstraZeneca Pharmaceuticals LP | 6 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| PFIZER INC. | 4 | $61 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Exact Sciences Corporation | 2 | $34 |
Products named: VRAYLAR, UBRELVY, TRINTELLIX, Ozempic, QULIPTA, JARDIANCE, CAPLYTA, MOUNJARO.
Industry payments across NE — which companies pay providers there.
